Sovereign regulatory bottlenecks are resolved by removing internal dissenters.
When high-priority therapeutic candidates face intense opposition from acting agency leadership over clinical risk-benefit profiles, administrative interventions and leadership purges are used to clear the path for approval.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The firing of the acting CDER director over her regulatory opposition directly cleared the path for Tzield's accelerated approval.
The departures of stricter regulatory internal dissenters paved the way for the FDA to reverse its previous refusal and endorse Moderna's mRNA vaccine.
Tzield ultimately received its accelerated approval to delay type 1 diabetes progression despite significant disputes over safety and efficacy.